# An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

> **NCT03842969** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 236 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** RO7234292 (RG6042)

## Key facts

- **NCT ID:** NCT03842969
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-23
- **Primary completion:** 2022-03-25
- **Final completion:** 2022-03-30
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03842969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03842969, "An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03842969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*